CTLA4 and neoplasm: In this tumor model, concurrent treatment with anti-CTLA4 and dietary ω-3 PUFAs supplementation resulted in an approximately 35% inhibition of tumor growth in mice, compared to treatment with anti-CTLA4 and the control diet (Fig. 3C).